Rexin-G™
(Retroviral Expression Vectors Bearing Inhibitory Genes)
The leading product of Epeius is REXIN-G™, which combines Epeius proprietary targeted vector system with a proprietary mutant cell-cycle control gene (i.e. anti-cancer gene). When given by intravenous infusions, REXIN-G™ has been shown to eradicate remote metastatic cancers in mice and to arrest cancer growth with shrinkage and necrosis of solid tumors in humans - determined by CT Scan and MRI – without eliciting systemic side effects. REXIN-G™ has been approved by the Philippine BFAD for systemic use in a Phase I/II clinical trial for all metastatic cancers. In the United States, REXIN-G™ is approved by the FDA for use in a Phase I clinical trial for metastatic pancreatic cancer. An ophthalmic formulation utilizing a similar TDS targeted gene delivery system, designated HAZIN-G, is currently under consideration by the FDA, for use in a proposed Phase I clinical trial for the reduction of severe cases of corneal scarring.
